Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $80
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating
AnaptysBio's Promising Therapeutic Agonist Pipeline Garners Buy Rating From David Risinger
AnaptysBio Is Maintained at Buy by Guggenheim
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating
"Buy" Rating for AnaptysBio Driven by Promising Preclinical Data on Rosnilimab's Ulcerative Colitis Treatment Potential
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $80
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and AnaptysBio (ANAB)
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $80
AnaptysBio Analyst Ratings
Wedbush Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $42
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating
J.P. Morgan Reaffirms Their Buy Rating on AnaptysBio (ANAB)
BTIG Initiates AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $55
AnaptysBio Price Target Raised to $30.00/Share From $20.00 by Truist Securities
Truist Financial Sticks to Its Hold Rating for AnaptysBio (ANAB)
AnaptysBio Analyst Ratings
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $55
AnaptysBio: Strong Buy Rating on Robust Equity Raise and Promising Clinical Pipeline
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Charles River Labs (CRL) and Akero Therapeutics (AKRO)